Bexmarilimab

CAS No. 2259301-27-2

Bexmarilimab( —— )

Catalog No. M36875 CAS No. 2259301-27-2

Bexmarilimab (FP-1305) is a highly potent, humanized anti-CLEVER-1 IgG4 antibody with an IC50 value of 4.51 nM, promoting immune conversion of tumor-associated macrophage phenotype M2 to M1, and can be used to study cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 301 Get Quote
5MG 820 Get Quote
10MG 1102 Get Quote
25MG 1582 Get Quote
50MG 2144 Get Quote
100MG 2817 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Bexmarilimab
  • Note
    Research use only, not for human use.
  • Brief Description
    Bexmarilimab (FP-1305) is a highly potent, humanized anti-CLEVER-1 IgG4 antibody with an IC50 value of 4.51 nM, promoting immune conversion of tumor-associated macrophage phenotype M2 to M1, and can be used to study cancer.
  • Description
    Bexmarilimab (FP-1305) is a potent humanized anti-CLEVER-1 IgG4-antibody with an IC50 value of 4.51 nM. Bexmarilimab is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab can be used in research of cancer.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2259301-27-2
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Hollmén M, et, al. Nonclinical Characterization of Bexmarilimab, a Clever-1-Targeting Antibody for Supporting Immune Defense Against Cancers. Mol Cancer Ther. 2022 Jul 5;21(7):1207-1218.?
molnova catalog
related products
  • IGF-I (24-41) TFA (1...

    IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions).IGF-I (24-41) (TFA) is amino acids 24 to 41 fragment of Insulin-like Growth Factor I (IGF-I).

  • IRE1α kinase-IN-1

    IRE1α kinase-IN-1 is a highly selective IRE1α (ERN1) inhibitor, with an IC50 of 77 nM. It displays 100-fold selectivity for IRE1α over the IRE1β isoform.

  • PKUMDL-WQ-2101

    PKUMDL-WQ-2101 is a selective allosteric inhibitor of phosphoglycerate dehydrogenase (PHGDH) with anti-tumor activity, it binds to site I.